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Cartilage hair hypoplasiaThe skeleton affords a framework and structural support for vertebrates, while also facilitating movement,
protecting vital organs, and providing a reservoir of minerals and cells for immune system and vascular homeo-
stasis. The mechanical and biological functions of the skeleton are inextricably linked to the size and shape of
individual bones, the diversity of which is dependent in part upon differential growth and proliferation. Pertur-
bation of bone development, growth and proliferation, can result in congenital skeletal anomalies, which affect
approximately 1 in 3000 live births [1]. Ribosome biogenesis is integral to all cell growth and proliferation
through its roles in translating mRNAs and building proteins. Disruption of any steps in the process of ribosome
biogenesis can lead to congenital disorders termed ribosomopathies. In this review, we discuss the role
of ribosome biogenesis in skeletal development and in the pathogenesis of congenital skeletal anomalies.
This article is part of a Special Issue entitled: Role of the Nucleolus in Human Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
1.1. Ribosome biogenesis
The ribosome is a large ribonucleoprotein machine that translates
mRNA into protein to synthesize all protein within the cell. The eukary-
otic ribosome catalyzes protein synthesis through distinct and yet
collaborative roles of its two subunits during translation. The small
40S subunit decodes mRNA sequence while the large 60S subunit
links amino acids through peptide bonds [2]. As ribosomes are univer-
sally responsible for the quality and quantity of proteins in all cells, ribo-
some production is highly regulated by, and integrated with, many
cellular processes including growth, proliferation, differentiation, and
hypertrophy.
Ribosome biogenesis, the process of making ribosomes, is a complex
and metabolically expensive endeavor that involves coordination of all
three RNA polymerases. Ribosomes are an assembly of 4 rRNAs tran-
scribed by RNA polymerases I and III, in addition to approximately 80
ribosomal proteins, accessory proteins and about 70 small nucleolare Nucleolus in Human Disease.
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ights reserved.RNAs (snoRNA) all transcribed by RNA polymerase II [2,3]. Ribosome
biogenesis beginswith transcription of both the 47S precursor ribosom-
al RNA (rRNA) by RNA polymerase I (RNA Pol I) in the nucleolus and the
5S rRNA by RNA polymerase III in the nucleus. Transcription of rRNA is
the rate-limiting step in ribosome production and accounts for about
60% of the overall transcription in eukaryotic cells [4]. Additionally, a
signiﬁcant proportion of mRNA transcription by RNA polymerase II in
the nucleus is also required for the production of the ribosomal proteins
[5]. Following transcription, the 47S rRNA precursor is cleaved into a
45S rRNA which is modiﬁed covalently at nearly 200 nucleotides by
snoRNPs, bound by ribosomal proteins, and further cleaved into 5.8S,
18S, and 28S rRNAs. Ultimately, the 18S rRNAand 32 small subunit ribo-
somal proteins (RPSs) are assembled into the 40S subunit while the 5S,
5.8S, and 28S with 47 large subunit ribosomal proteins (RPLs) are
assembled into the 60S ribosomal subunit. These ribosomal subunits
are then exported to the cytoplasm where they unite to form the
translationally active mature 80S ribosome [2,6].
As ribosomes determine the capacity for protein production
and their synthesis commandeers much of the cell's metabolic efforts,
ribosome biogenesis determines growth, cell division rates, and survival
[7]. Given the ribosome's universal importance in all cell types, it is re-
markable that disruptions in ribosome biogenesis lead to congenital
ribosomopathies with very speciﬁc clinical phenotypes that include de-
fects in the craniofacial, axial and limb skeleton (Fig. 1). Herewe discuss
how the etiology and pathogenesis of ribosomopathies can reveal new
information about the role of ribosome biogenesis in proliferation,
growth, and differentiation in skeletal development.
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Fig. 1. Schematic diagram summarizing the major components of ribosome biogenesis and the intersection of speciﬁc genes that leads to the pathogenesis of distinct ribosomopathies.
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Bones, in their many shapes and sizes, underlie form and function of
the vertebrate skeleton. The 206 bones in the human skeleton protect
our vital organs, provide a reservoir of minerals, facilitate movement,
and underlie the basis for physical appearance. These mechanical and
biological functions are possible because bones come in a multitude of
shapes and sizes—long, short, ﬂat, and irregular. Skeletal diversity arises
in the developing embryo by a stepwise series of events that demarcate
when, where, and how bone is built.
Skeletal development begins when loose networks of mesenchymal
cells coalesce and condense, preﬁguring mature cartilage and bone.
Different mesenchymal populations give rise to anatomically distinct
groups of bones. Neural crest-derived mesenchyme forms bones in
the face, jaw and rostral calvariumwhereasmesoderm-derivedmesen-
chyme forms bones in the caudal calvarium, vertebral column, rib cage,
and limbs. These mesenchymal populations build bone through either
endochondral or intramembranous ossiﬁcation. During endochondral
ossiﬁcation the mesenchyme initially forms a cartilage scaffold that is
later replaced by bone. During intramembranous ossiﬁcation, the mes-
enchyme differentiates directly into bone. Skeletal elements that devel-
op through endochondral ossiﬁcation are largely mesoderm-derived,
while those that form by intramembranous ossiﬁcation are almost
exclusively neural crest-derived and localized to the craniofacial region
[8,11].The commencement of skeletal development is followed by a long pe-
riod of growth that progresses throughout fetal development and con-
tinues postnatally through adolescence. The directionality of growth,
which modiﬁes the size and shape of bones, is differentially regulated
by endochondral and intramembranous ossiﬁcation. Intramembranous
ossiﬁcation leads to appositional growth, adding new bone at the leading
edge or surface to increase thickness or length. During this process oste-
oblasts deposit osteoidmatrix against the bone's surfaces or at the osteo-
genic fronts. Addition of bone at the leading edge, while useful for
growing ﬂat bones in the skull, is not compatible with bones whose
ends articulate into a moving joint. This is solved by endochondral ossiﬁ-
cation, which promotes interstitial growth from the bone's center to
increase its length [8,11].
A stratiﬁed cartilage structure known as the growth plate is respon-
sible for interstitial growth within endochondral bones. The growth
plate, a holdover of the precartilage condensation in the epiphysis, is
arranged into four functional zones that represent the developmental
progression of endochondral ossiﬁcation (Fig. 2). The resting zone
holds a reservoir of chondroprogenitor cells that when activated move
into the proliferative zone where they rapidly divide to form columnar
stacks parallel to the long axis of the bone. This transition is regulated
by the Sox trio: Sox 5, 6 and 9 [12,13]. Proliferating chondrocytes then
transition into the zone of hypertrophy were they swell several times
their original volume and secrete copious amounts of matrix rich in col-
lagen [14]. This process of chondrocyte maturation is regulated by the
proliferating  
chondrocyte 
chondroprogenitor
mature  
chondrocyte 
hypertrophic  
chondrocyte 
resting 
 zone 
proliferative  
zone 
pre-hypertrophic 
 zone 
hypertrophic  
zone 
bone 
Sox9 
Sox5/6 
Sox5/6 
Mef2c/d 
Runx3 
Mef2c/d 
apoptosis
osteoprogenitor
osteoblast Osx
osteocyteAtf4 
Growth  
Plate 
Runx2 
Runx2 
Fig. 2. Skeletal development proceeds either through endochondral or intramembranous ossiﬁcation. This schema of the stratiﬁed growth platewithin a long bone depicts the transition of
the chondroprogenitor cell through the developmental progression of endochondral ossiﬁcation, which includes proliferation, maturation, hypertrophy and ultimately cell death.
Osteoprogenitor cells then invade the void left by hypertrophy, differentiate into osteoblasts, and maturate into osteocytes. Differentiation and maturation of osteoprogenitor cells is
indistinguishable between endochondral and intramembranous ossiﬁcation.
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trophic chondrocytes ultimately undergo cell death in the zone of ossi-
ﬁcation and osteoblasts invade the void where the calciﬁed cartilage
matrix has been eroded by matrix metalloproteinases and osteoclasts.
In adulthood, when the long bones have reached their full length, the
growth plate cartilage becomes fully replaced by bone.
Chondrocytes require high translational capacity to meet the de-
mands of proliferation, collagen matrix production, and then cellular
hypertrophy within the stratiﬁed growth plate. Although a speciﬁc
role for ribosome biogenesis in chondrocyte proliferation remains to
be determined, the skeletal phenotypes of speciﬁc ribosomopathies
infer such a connection. Moreover, the importance of ribosome biogen-
esis to general cell growth is well known. The role of ribosome biogen-
esis in chondrocyte maturation however is clearer due to themolecular
link between rRNA transcription and transcriptional regulators of chon-
drocyte hypotrophy [15,16]. Runx2 and Runx3 associate with rDNA and
regulate transcription through interactions with UBF1, an architectural
factor that promotes transcription by RNA Pol I [17,19]. However, it is
not known whether Runx2 and/or Runx3 regulate rRNA transcription
in chondrocytes. Nonetheless, UBF1 is an ideal candidate to control
chondrocyte hypertrophy as regulation of UBF1 is the key to the
increased ribosome biogenesis and protein accumulation observed in
association with cardiomyocyte hypertrophy [20].
While bone can be built through direct or indirect ossiﬁcation, the
role of the osteoblasts in these developmentally distinct processes is
indistinguishable. Osteoprogenitor cells, whether located within the
periosteum of endochondral bones or the mesenchymal condensation
and osteogenic front of intramembranous bones, experience the sameprocess of osteoblast differentiation (Fig. 2). Osteoprogenitors are
induced to differentiate by growth factors including FGF and BMP
(reviewed in [21,22]). Acquisition of osteoblast cell fate requires the ac-
tivity of the transcription factors Runx2, Osx/SP7, and Atf4 to promote
expression of osteoblast speciﬁc genes including those that encode oste-
oidmatrix proteins such as type I collagen, osteocalcin, and osteopontin
[23,25]. Once secreted, this collagen-rich osteoid matrix mineralizes
upon binding to calcium salts brought to the region through neighbor-
ing vasculature. A subpopulation of osteoblasts become entrapped
by the mineralized matrix and matures into osteocytes that actively
regulate the lifelong process of bone turnover.
Regulators of osteoblast differentiation are unquestionably integrated
with ribosome biogenesis. For example NO66, a nucleolar demethylase
implicated in ribosome assembly and maturation, interacts with OSX/
SP7 and inhibits OSX-mediated promoter activation in preosteoblasts
thereby negatively regulating osteoblast differentiation [26,27]. The
mostwell establishedmolecular connector between ribosome biogene-
sis and osteoblast differentiation is Runx2, the master regulator of bone
formation. Runx2 performs two essential functions in osteoprogenitor
commitment. Firstly, it promotes osteoblast differentiation by tran-
scriptionally activating bone-speciﬁc genes, and secondly it restricts
cell division through inhibition of UBF1 and attenuation of rDNA tran-
scription [17,28,31]. Integrating ribosome biogenesis with regulators
of bone formation is a means to couple and coordinate osteoprogenitor
cell proliferation and differentiation during skeletal development.
Thus ribosome biogenesis plays a critical role in intramembranous
ossiﬁcation of the neural crest-derived craniofacial skeleton and endo-
chondral ossiﬁcation of the mesoderm-derived limb skeleton. The
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proteins and regulators of ribosome biogenesis can cause hypoplasia of
the craniofacial bones, shortening of the long bones, and anomalies of
the digits. This is exempliﬁed in congenital ribosomopathies with
skeletal defects, the etiology and pathogenesis of which are discussed
in this review.
1.3. Treacher Collins syndrome
Treacher Collins syndrome (TCS1, MIM 154500; TCS2, MIM
613717), also known as Franschetti–Zwahlen–Klein syndrome and
mandibulofacial dysostosis, is a congenital birth defect that affects head
and facial development [32,33]. TCS is most notably characterized by
midface hypoplasia encompassing the maxilla, dentary and zygomatic
complex bones [34]. Individuals with TCS also often exhibit underdevel-
oped external ears, which together with atresia of the external auditory
canals and anomalies of the middle ear ossicles can lead to conductive
hearing loss [35]. Abnormalities in brain development including micro-
cephaly, mental retardation and psychomotor delay can present as part
of the clinical spectrum of TCS, however, these features present in
fewer than 5% of affected individuals [36,39].
Treacher Collins syndrome occurs with a frequency of 1 in 10,000–
50,000 births and arises primarily due to autosomal dominant muta-
tions in the TCOF1, gene [40]. Changes identiﬁed in TCOF1 include splice
site, missense and nonsense mutations as well as insertions and dele-
tions. Of the more than 200 family speciﬁc mutations in the TCOF1
gene that have been recorded to date, deletions ranging in size from 1
to 40 nucleotides appear to be the most common. Interestingly, a
reoccurring 5 bp deletion in exon 24 accounts for nearly 20% of TCS
cases. (http://genoma.ib.usp.br/TCOF1_database/). Recently however,
individuals with TCS but without TCOF1mutations were found through
whole exome sequencing to carry mutations in POLR1C or POLR1D [41].
Therefore to date, the genetic causes of TCS are attributable to autoso-
mal dominant mutations in TCOF1, autosomal dominant mutations in
POLR1D or autosomal recessive mutations in POLR1C [41].
Despite the identiﬁcation and high penetrance of causative gene
mutations underlying TCS, there is considerable inter- and intra-
familial variation in the severity of the disorder [42,43]. However,
there is no apparent correlation between parental origin or type of path-
ogenic mutation, whether sporadic or familial, male or female, with the
severity of Treacher Collins phenotype. This lack of a genotype–pheno-
type correlation in TCS [38,44,47], suggests that modiﬁers may be in-
volved. Therefore, environmental factors or genetic background, may
be contributing factors to the clinical variability of developmental
anomalies observed in TCS patients [48].
TCOF1 encodes a putative nucleolar phosphoprotein termed Treacle
[40], that has been observed to co-localizewith upstreambinding factor
1 (UBF1) and RNAPol I in nucleolar organizing regionswithin thenucle-
olus, where it plays an essential role in rDNA transcription [49,50]. Trea-
cle has also been shown to participate in ribosomal RNA processing as
an integral component of the human Nop56-associated pre-ribosomal
ribonucleoprotein complexes, which 2′O-methylates pre-ribosomal
RNA in the nucleolus during the early stages of pre-RNA processing
[49,50]. Collectively, this implies that Treacle speciﬁcally regulates mul-
tiple steps during the process of ribosome biogenesis and that deﬁcient
ribosome biogenesis may underlie the etiology of the characteristic fea-
tures of TCS.
Consistent with this idea, a Tcof1 loss-of-function mouse model of
TCS [48], exhibits decreased levels of 28S rRNA generation and defective
maturation of the 60S ribosomal subunit. Inadequate ribosome biogen-
esis is known to cause nucleolar stress activation of the p53 pathway,
resulting in p53-mediated cell death. Correlating with this phenome-
non, extensive p53 dependent apoptosis was observed throughout the
neuroepithelium and including pre-migratory neural crest cells in
E8.0-10.5 Tcof1+/− embryos. While Tcof1 is widely expressed through-
out the embryo during these developmental stages, Tcof1 expressionbecomes speciﬁcally elevated in the neuroepithelium and neural crest
cell derived facial mesenchyme [51]. Consequently, extensive cell
death in the neuroepithelium reduces the neural crest cell population
by nearly 25% in Tcof1+/− embryos compared to wild-type controls
[51,52]. This is signiﬁcant to the TCS phenotype, because neural crest
cells are the skeletal precursors of the face and their deﬁciency can
lead to incomplete formation of the craniofacial bones, cartilage and
connective tissues. Deﬁciencies of neural crest cell development are
not unique to TCS. In fact, many craniofacial anomalies are attributed
to deﬁciencies in neural crest cell development. Together, these results
mechanistically illustrate how Tcof1 can inﬂuence neural crest cell for-
mation and survival through the regulation of ribosome biogenesis.
Interestingly, pharmacological and genetic suppression of p53 has
been shown to prevent neuroepithelial apoptosis in Tcof1+/− mouse
embryos, preserving normal formation and survival of neural crest
cells. Consequently, inhibition of p53-dependent cell death, prevents
cranioskeletal abnormalities in amousemodel of TCS [52]. These results
in animal models demonstrate that Treacher Collins syndrome may be
clinically preventable and provide hope for future therapy. Thus the
TCS animal models that phenocopy the salient features and variability
observed in humans with TCS have been invaluable in uncovering the
mechanisms underlying the etiology and pathogenesis of this severe
congenital craniofacial disorder [51,52].
The identiﬁcation of causative mutations in POLR1D and POLR1C in
association with TCS is consistent with the classiﬁcation of TCS as a
ribosomopathy disorder. POLR1C and POLR1D constitute subunitswith-
in the catalytic core of RNAPol I and III. Similar to the role of TCOF1 as an
RNA Pol I binding factor and regulator or rDNA transcription and pre-
ribosomal RNA processing, POLR1C and POLR1D may also play critical
roles in rDNA transcription. Therefore, in the future it will be critical to
develop new animal models for TCS through mutations in POLR1C and
POLR1D, determine the precise function of POLR1C and POLR1D, and ex-
amine any degree of overlapping function with TCOF1. The identiﬁca-
tion of mutations in these three distinct genes involved in ribosome
biogenesis, a process which underpins cell growth and proliferation,
strongly indicates that TCS is a true ribosomopathy disorder.
1.4. Postaxial acrofacial dysostosis
Postaxial Acrofacial dysostosis (POADS,MIM 263750) also known as
Miller, Genee–Wiedemann, or Wildervanck–Smith syndromes, is an
acrofacial dysostosis syndrome that presents with abnormalities in the
craniofacial and limb skeleton. The spectrum of craniofacial anomalies
includes micrognathia, orofacial clefts, malar hypoplasia and cup-
shaped ears. Limb defects are conﬁned to the postaxial limb skeleton
and include absence of either the ﬁfth or both the fourth and ﬁfth rays
of the hands and feet, and ulnar and ﬁbular hypoplasia [53,55]. The
craniofacial features of POADS share considerable similarity to the key
features of TCS.
POADS is caused by compound heterozygous mutations in the gene
coding for dihydroorotate dehydrogenase (DHODH) [56,57], an enzyme
that participates in the mitochondrial electron transport chain and is
required for de novo pyrimidine synthesis. DHODH catalyzes the oxida-
tion of dihydroorotate (DHO) to orotic acid, which is subsequently con-
verted to uracil monophosphate. Uracil is a constituent base of RNA and
is therefore integral to ribosome biogenesis. In vivo and in vitro assays
have shown that DHODH activity from POADS-associated alleles is
diminished. This implies that affected individuals have a deﬁciency of
de novo pyrimidine synthesis, which is consistent with the need for a
threshold level of DHODH activity. Furthermore it suggests that a deﬁ-
ciency in ribosome biogenesis may be an underlying feature of POADS.
Similar to the etiology of TCS, it is surprising that mutations in
DHODH would lead to such tissue speciﬁc phenotypes since uracil and
RNA synthesis are global processes. However, analyses ofDhodh expres-
sion inmouse embryos have uncovered spatiotemporally speciﬁc activ-
ity in the pharyngeal arches, forelimbs, hindlimbs and somites [57]. It is
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the structures affected in POADS syndrome and that DHODH loss-
of-function may therefore result in spatiotemporally dynamic rate-
limiting effects on cell growth and proliferation. Consistent with this
idea, zebraﬁsh treated with leﬂunomide, an inhibitor of DHODH show
an almost complete abrogation of neural crest cell development due
to blocked transcriptional elongation of genes critical for neural crest
cell function [58]. This suggests that deﬁcient numbers of neural crest
cells can account for the cellular basis of POADS syndrome in a mecha-
nism highly analogous to that underlying the pathogenesis of TCS.
It is important to note however that mutations in Uridine
Monophosphate Synthetase (UMPS), which functions immediately
downstream of DHODH, result in the pathogenesis of orotic aciduria.
Orotic aciduria presents with the classic feature of reduced pyrimidine
availability which is megaloblastic anemia. Furthermore, orotic aciduria
can be effectively treated with dietary uridine supplementation, dem-
onstrating that the lack of pyrimidines underlies the orotic aciduria dis-
ease state. This raises the question as towhy individuals with POADS do
not have megaloblastic anemia or conversely, why individuals with
orotic aciduria do not exhibit skeletalmalformations.While it is possible
that phenotypic overlap between these disorders has gone unrecog-
nized, it seems more plausible that the underlying basis of POADS may
not be restricted to deﬁcient pyrimidine synthesis. Furthermore, there
is no clear evidence to date for nuclear localization of DHODH. It will
be critical therefore in the future, to characterize the dynamic localiza-
tion of DHODH, as well precisely determine the biochemical functions
of DHODH and the cellular basis of POADS syndrome in vivo, through
mammalian animal models of Dhodh loss-of-function.
1.5. Diamond–Blackfan anemia
Diamond–Blackfan anemia or Inherited Erythroblastopenia (DBA,
MIM 105650) is a congenital erythroid dysplasia, where affected indi-
viduals typically present with anemia (deﬁciency of red blood cells).
In addition, DBA is primarily characterized by a selective decrease or
absence of erythroid precursors aswell as reticulocytopenia andmacro-
cytosis [59]. However, individuals with DBA often (40–62%) present
with a range of craniofacial and cardiac defects as well as thumb abnor-
malities [59]. Interestingly, the craniofacial phenotype of DBA has con-
siderable overlap with TCS and can include cleft palate and microtia.
Taken togetherwith the fact that the three genesmutated in association
with TCS all inﬂuence ribosome biogenesis, this raised the possibility of
a similar role for ribosome biogenesis in neural crest cell formation in
the pathogenesis of ribosomopathies such as DBA. In contrast to TCS,
which results from the deﬁcient transcription of rRNA, DBA is caused
by mutations in genes encoding ribosomal proteins including RPS17,
RPS19, RPS24, RPL5, RPL11, and RPL35A (reviewed in [59,60]). Currently
however, these mutations account for only about 50% of individuals
with DBA, illustrating there is still much to be learned about the etiology
of DBA.
DBA patients that exhibit craniofacial and cardiac anomalies, more
often have mutations in RPL5 than any other RP gene linked to DBA
[61]. Although this suggests that theremay be spatiotemporally speciﬁc
roles for individual ribosomal proteins, there is no clear evidence to date
of a role for RPL5 in cranial or cardiac neural crest cell development.
Interestingly, zebraﬁsh rpl11morphants exhibit hematopoietic defects
[62], as well as diminished activity of neurogenic markers [63].
Although not formally investigated, the substantial apoptosis observed
in these embryos could disrupt neural crest cell formation and account
for diminished expression of neurogenic markers. Consistent with this
idea, inhibition of p53 prevented DBA in rpl11morphants [63]. Further-
more p53 inhibition was also successful in preventing developmental
anomalies in mice and zebraﬁsh with mutations in Rps19/rps19
[64,65]. These results are very similar in principle to the prevention
of TCS in Tcof1+/− mice [52] implying some commonality to their
pathogenesis.Remarkably, dietary supplementation with L-leucine considerably
improves the phenotype of mouse and zebraﬁsh models of DBA
[66,67]. For example, when rps14 or rps19 morphant zebraﬁsh were
grown in L-leucine supplemented media, their craniofacial abnormali-
ties were substantially ameliorated [66]. Furthermore, it has also been
reported, albeit on a very limited scale, that dietary L-leucine supple-
mentation successfully treated the anemia in some individuals
with DBA [68,69]. Mechanistically it is thought that TORC1 (target of
rapamycin complex 1, also known asmTOR)which is an important reg-
ulator of ribosome biogenesis, cell growth and cell proliferation, is acti-
vated by amino acids such as L-leucine. Leucyl-tRNA sythetase (LeuRS),
which charges tRNAwith leucine facilitates TORC1 activity [66,70] lead-
ing to phosphorylation of the RNA Pol I initiation complex and conse-
quently stimulation of rDNA transcription [71,72]. More speciﬁcally,
phosphorylation of 4E-BP1 by TORC1 releases it from the translation
initiation complex, allowing for translation of ribosomal proteins [73].
Furthermore, TORC1 also governs the phosphorylation of Maf1, which
is an important regulator of RNA Pol III [74,75].
Although the impact of L-leucine on neural crest cell development
has not been thoroughly investigated, dietary supplementation with
L-leucine could provide a therapeutic option for the prevention of
other neurocristopathy disorders in which deﬁcient ribosome biogene-
sis underlies their manifestation. Deﬁcient ribosome biogenesis can
cause nucleolar stress activation of p53 and cell death. Hence the cranio-
facial anomalies observed in DBA are likely caused by p53 dependent
neuroepithelial cell death, diminished NCC formation and proliferation
in a similar fashion to the pathogenesis of TCS. In support of this idea
Rps19-deﬁcient mice, administered L-leucine in their drinking water
exhibited a down-regulation of p53 and subsequently, improved hema-
topoiesis [67]. A thorough exploration of the dynamics of neural crest
cell development in speciﬁc animal models of DBA is still needed in
the future to facilitate a better understanding of the functions of
ribosomal proteins in the pathogenesis of DBA.
1.6. Roberts syndrome
Roberts syndrome (RBS, MIM 268300) is characterized by pre- and
post-natal growth retardation, bilateral symmetric limb reduction, and
craniofacial abnormalities including hypertelorism, cleft lip and palate,
and hypoplastic nasal alae [76]. RBS is inherited in an autosomal reces-
sive manner and is caused by mutations in the ESCO2 gene [77], which
have been recently shown to inﬂuence production of rRNA [78].
ESCO2, Establishment of Cohesion 1 Homolog 2 (Eco1 in yeast), is an
acetyl transferase important in assembly of Cohesin. Cohesin is a com-
plex of proteins which binds chromosomes and holds sister chromatids
together from DNA replication to cell division [79]. However, Cohesin
also has other cellular roles including binding genes with paused RNA
Polymerase, facilitating DNA looping to bring together enhancers and
promoters, and DNA repair (reviewed in [80]).
The speciﬁc developmental anomalies associated with mutations in
ESCO2 have begun to be investigated in animal models. Antisense
morpholino oligonucleotide knockdown of esco2 in zebraﬁsh, results
in embryos with a smaller head and eyes, and incorrectly shaped so-
mites at 24 hpf [81]. Later in development, additional features such as
abnormal pigmentation, reduced craniofacial cartilage and pectoral ﬁn
growth, and cardiac defects became apparent. Distorted spindles and
disorganized chromosomes were seen in the mitotic cells of esco2
morphants, suggesting that these cells are subsequently unable to pro-
ceed through mitosis and undergo apoptosis. Therefore, similar to TCS
and DBA, it seems likely that the RBS phenotype may be related, at
least in part, to increased cell death and death of neural crest precursors.
However, in contrast to TCS and DBA, the cell death in esco2morphants
is p53 independent [81].
Studies in yeast and human cell lines revealed that eco1 mutants
exhibited defects in ribosome biogenesis including reduced protein
translation [78]. Speciﬁcally, production of the methylated 25S and
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disrupted in eco1 mutants [78]. Consistent with this, ﬁbroblasts from
individuals with RBS showed diminished rRNA production and protein
synthesis. This suggests a similar disregulation of ribosome biogenesis
underlies the pathogenesis of TCS, DBA and RBS.
Cohesin proteinsmay therefore normally facilitate production of ribo-
somal RNA and protein translation. Although RBS is classically considered
a cohesinopathy [82], RBS can also be classiﬁed as a ribosomopathy given
the features of diminished ribosome biogenesis, nucleolar disruption, and
apoptosis. It remains to be determinedwhat impact these cohesinopathy
mutations have on neural crest cell development, however, future work
with RBS models may reveal novel roles for esco2 in neural crest forma-
tion, migration, or differentiation and provide new information for the
development of therapies to improve the quality of life for RBS patients.
1.7. Shwachman–Diamond syndrome
Shwachman–Diamond syndrome (SDS, MIM 260400) is another
ribosomopathy disorder that encompasses skeletal abnormalities and
bone marrow failure [83,84]. In fact, abnormal dermal bone formation
and abnormal endochondral bone formation are characteristic features
of SDS. This initially manifests as delayed bone aging and maturation in
association with abnormal growth plate and metaphysis development,
resulting in short stature, but it also leads to progressive deleterious
pathological conditions including osteopenia, osteoporotic vertebral
anomalies and fractures [83,85]. Similar to TCS, there is considerable
variability in the severity and extent of skeletal phenotypes in individ-
uals with SDS, despite patients within the same family carrying identi-
cal mutations [86].
SDS occurswith an estimated incidence of 1 in 50,000 live births and
approximately 90% of individuals with SDS carry biallelic mutations in
SBDS [87]. Thus SDS is an autosomal recessive disorder arising frommu-
tations in the SBDS gene [87]. These mutations are thought to be likely
hypomorphic, since by comparison, mice that are homozygous null for
mutant alleles of SBDS exhibit early embryonic lethality, illustrating
that SBDS is essential for normal development [88].
Analyses in mammalian cells imply that SBDS performs multiple
functions in distinct processes during development. These include
ribosome biogenesis [89], cell motility [90,91], and the regulation of
oxidative stress [92] and mitotic spindle stabilization [93]. However,
analyses in yeast and human cells support the notion that SDS is a disor-
der of ribosome biogenesis. Sdo1, the yeast ortholog of SBDS, has been
shown to localize to the nucleolus and function in ribosome biogenesis
[94,95]. Furthermore, cells derived from individuals with SDS exhibit
perturbed activity of ribosome biogenesis associated genes, particularly
those that govern the processing of tRNA andmRNA [96]. Moreover, the
activity of ribosomal proteins known to inﬂuence cell survival and
growth was also similarly decreased [97]. SBDS however, inﬂuences
not only early steps in the ribosome biogenesis process, but also late
steps in ribosomal subunit maturation and function. The eukaryotic ini-
tiation factor 6 (eIF6), typically keeps the 60S subunit functionally inac-
tive. However, a pre-requisite for the initiation of 80S ribosome
translational activity is the release of eIF6 from the 60S ribosome and
this release is facilitated by SBDS [98].
The varied clinical phenotypes observed in SDS have been hypothe-
sized to reﬂect the level of residual SBDS protein expression coupled
with critical threshold requirements for SBDS function inmeeting trans-
lational demands in different tissues at various times during develop-
ment [99,100]. Although, the expression and role of SBDS in cartilage
and bone remains unknown, chondrocytes and osteoblasts of the skele-
tal system are all characterized by high protein secretory capacity.
Impaired SBDS function may therefore mediate its effects through per-
turbation of global protein translation or more likely through defective
translation of critical proteins involved in axial and limb skeletal devel-
opment. Either way, SDS is a ribosomopathy, caused primarily by
impaired release of eIF6 and deﬁcient 80S translational activity as aconsequence of mutations in the function of the ribosome assembly
factor SBDS.
1.8. Cartilage hair hypoplasia
Cartilage hair hypoplasia (CHH, MIM 250250), which is also known
asmetaphyseal chondrodysplasia McKusick type [101], is characterized
by short-limb dwarﬁsm with adults ranging in height from 104 to
149 cm. Metaphyseal or spondyloepiphyseal dysplasia underlie CHH
and similar short-limb dwarﬁsm conditions. The limbs and ribs are
most affected, with sparing of the spine and skull. Radiographic studies
reveal short and thick tubular bones, with splaying and irregular
metaphyseal borders of the growth plates that are widened, scalloped
and irregularly sclerotic [102,103]. The costochondral junctions are sim-
ilarly affected. These metaphyseal changes are present at birth and are
distinguished from other metaphyseal chondrodysplasias by more
severe involvement of the knee region than in the proximal femora
[104]. CHH is a variant of short-limb dwarﬁsm in which ﬁne, thin and
sparse hair is also present, beginning in the newborn period. Other com-
mon features include ligamentous laxity, defective T-cell and/or B-cell
mediated immunity, hypoplastic anemia, and variable aganglionosis of
the intestine, which leads to gastrointestinal anomalies such as
Hirschsprung disease in some individuals [103,105,107].
First described in Amish people [101] the incidence of CHH in the
Amish is 1 in 1340 births, with a carrier frequency of 1:19. In contrast,
in Finland, CCH presents with a frequency of 1 in 18,000–23,000 live
births with an estimated carrier rate of 1:76 [103]. CHH is an autosomal
recessive disorder with equal male-to-female frequency that arises
frommutations in the gene RMRP, whichmaps to 9p12 [108]. The foun-
der mutation 70ArG contributes to 92% of Finnish and 48% of non-
Finnish patients with CHH [109].
TheRMRP gene encodes theuntranslated RNA subunit of the ribonu-
cleoprotein endoribonuclease processing complex, RNaseMRP. RMRP is
therefore a snoRNA that localizes to the nucleolus and mitochondria of
cells. Within the nucleolus, snoRNAs form small nucleolar ribonucleo-
protein complexes (snoRNPs) that regulate the synthesis of ribosomal
RNA [110]. The yeast ortholog of RMRP is nme1, and it functions in
(i) ribosome synthesis, via nucleolar cleavage of preribosomal RNA
(pre-rRNA) and rRNA production; (ii) the generation of RNA primers
for mitochondrial DNA replication, via cleavage of RNA [110]; and
(iii) in governing cell growth via degradation of cell cycle-regulated
mRNA [111]. Mutation of nme1 affects endonuclease cleavage of 5.8S
rRNA at the ITS-1 A3 site, which consequently disrupts 60S ribosomal
assembly [112,113]. The magnitude of the effect on nme1 mutant
yeast cell growth, is directly proportional to the severity of the defect
in 5.8S rRNA-processing [114]. Furthermore, deﬁcient production or in-
corporation of a single subunit of the 60S ribosome, can lead not only to
the disintergration of the entire 60S ribosome, but can also negatively
impact regulatory feedback signals from the secretory machinery on
ribosome biogenesis [115].
Overexpressing RMRP in human ﬁbroblasts substantially elevates
production of the cleaved or processed 5.8S rRNA and consequently
accelerates cellular growth rates [116]. In contrast the mutated form
of RMRP found in individuals with CHH elicits minimal cleavage or pro-
cessing of the 5.8S rRNA. Furthermore, cells overexpressing the CCH
variant of RMRP showed signiﬁcantly decreased cyclin A2 levels and
signiﬁcantly increased cyclin B2 mRNA levels. This is indicative of de-
creased mRNA degradation, which leads to mitotic delay. Thus RMRP
gene mutations affect cell growth through their perturbation of both
ribosomal assembly and cyclin-dependent cell–cycle regulation. These
alterations are consistent with slower cell cycle rates that can account
for the decreased rates of growth in the clinical phenotype of CHH.
Mutations in RMRP have also been found responsible for two
other autosomal recessive skeletal dysplasias. Metaphyseal dysplasia
without hypotrichosis (MIM 250460) is an allelic variant of CHH that
exhibits only skeletal manifestations [117,118]. The RMRP mutations
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ity, speciﬁcally leading to poor processing of rRNA while allowing for
normal mRNA processing of B-cyclin [116]. This disorder is character-
ized by midface hypoplasia and extremely short stature with defects
in the growth plate including marked hypocellularity of the resting
cartilage, severely reduced numbers of proliferating chondrocytes, and
diminished columnization of the hypertrophic zone [119,120].
1.9. Bowen–Conradi syndrome
Bowen–Conradi syndrome (BWCNS; MIM 211180) is characterized
by micrognathia, a distinct, prominent nose, pre-natal and post-natal
growth retardation togetherwith joint anomalies such as camptodactyly.
Other clinical features of BWCNS can include microcephaly and psycho-
motor delay [121,122]. This spectrumof anomalies overlapwith those as-
sociated with cerebro-oculo-facial-skeletal syndrome and trisomy 18
disorders. Nearly all individuals born with BWCNS are from Hutterite
families of the Canadian Prairies and die within the ﬁrst year of life.
Recently a c.400A/G, p.D86G mutation in the EMG1 gene was identiﬁed
in association with BWCNS illustrating that BWCNS is an autosomal
recessive disorder [123] and one that occurs with an incidence of about
1 in 355 [122].
EMG1 can function as a dimer ormultidimer and the D86Gmutation
is thought to alter the structure of the EMG1 protein. Although this re-
sults in diminished levels of EMG1 protein in ﬁbroblasts derived from
BWCNSpatients, the effect of theD86Gmutation is to increase the inter-
action of EMG1 subunits, 10-fold [123]. TheD86 residue in EMG1,which
is consistently mutated in association with BWCNS is conserved across
all orthologs analyzed to date [123]. Known as Nep1 in yeast, Emg1 is
a constituent of the small subunit (SSU) processome, a ribonucleopro-
tein complex required for 18S rRNA biogenesis [124]. During the com-
plex process of ribosome biogenesis, precursor 35S rRNA undergoes
considerable modiﬁcation and processing to generate mature 5.8S,
25S, and 18S rRNA [125]. EMG1 is a SPOUT methyltransferase, which
methylates the ribose 2′–OH group, guanine N1, or uridine N3 of rRNA
or tRNA as part of this maturation process [126]. More speciﬁcally,
EMG1 is intimately involved in regulating the snoRNP complex that
2′–OH ribose methylates 18S rRNA at G1570. Furthermore, EMG1
plays a critical role in recruiting the SSU processome protein, Rps19
[127]. Interestingly, the depletion of individual components of the SSU
processome result in G1 cell-cycle arrest in yeast [128]. A G1/S check-
point helps to ensure that prior to cell division, sufﬁcient levels of ma-
ture ribosomes are achieved to support cell division and proliferation.
This supports the concept that cell cycle progression is intimately con-
nected to ribosome biogenesis [129,130].
Thus through its participation in the SSU processome, EMG1 inﬂu-
ences ribosome biogenesis maturation and processing in multiple
ways. Speciﬁcally, EMG1 appears to play critical roles in the maturation
of 18S rRNA and subsequently 40S ribosome biogenesis through the
process of methylation [131,132]. EMG1 is broadly expressed in most
embryonic and adult tissues with elevated levels in organs such as the
brain, heart, liver, stomach and kidney. EMG1 loss-of-function might
therefore render cells incapable of generating enough 40S ribosomes
to support normal rates of cell division and proliferation during both
embryonic development and adult homeostasis.
2. Conclusions
The demonstration that perturbation of ribosome biogenesis under-
lies many skeletal disorders in humans is perhaps not surprising given
the importance of proliferation and the dramatic changes in cells size
that occur during cartilage and bone development. However, protein
synthesis is a ubiquitous requirement in cells, tissues and organs, and
furthermore ribosomal proteins are very widely expressed. Thus the
fact that there is considerable variability in the phenotypic spectrum
of individual ribosomopathy skeletal disorders, and also that theseverity of individual phenotypes varies combined with distinct
modes of inheritance, presents complex challenge for the ﬁeld tomech-
anistically understand. For example, some syndromes speciﬁcally affect
the craniofacial skeleton (Treacher Collins, syndrome), while other
syndromes encompass combinatorial malformation of the craniofacial,
axial and/or limb skeletal systems (Diamond–Blackfan anemia;
Postacrofacial dysostosis; Roberts syndrome; Schwachman–Diamond
syndrome; Cartilage hair hypoplasia; Bowen–Conradi syndrome). Sim-
ilarly bonemarrow failuremay ormay not present as part of the clinical
spectrum of skeletal anomalies. Bonemarrow failure is not a recognized
component of Treacher Collins syndrome or Postacrofacial dysostosis,
but is a deﬁning feature of Diamond–Blackfan anemia, Shwachman–
Diamond syndrome and Cartilage hair hypoplasia. This raises the
fundamental question of how mutations in genes critical for ribosome
biogenesis, whichmight normally have global or widespread roles dur-
ing organism development, can lead to such selective defects.
The characteristic of broadly expressed genes exhibiting cell or tis-
sue speciﬁc functions is not unique or exclusive to ribosomal genes.
However at present there does not appear to be a single unifying factor
that collectively links ribosomal genes and proteins except for their
roles in various aspects of ribosome biogenesis and the clinical patho-
genesis of ribosomopathies. One possibility however, is that the clinical
differences and their variability may be explained by the types of alter-
ation and the magnitude of their effect on ribosome biogenesis. For
example, distinct mutations in RMRP give rise to the allelic conditions
of Cartilage hair hypoplasia and Anauxetic dysplasia. Mutations in
RMRP that reduce ribosomal RNA cleavage are associated with bone
dysplasia, whereas mutations that affect mRNA cleavage are associated
with hair hypoplasia, immunodeﬁciency, and dermatologic abnormali-
ties [133]. This also raises a number of issues concerning the spatiotem-
poral dynamics of ribosome biogenesis andwhether different threshold
levels of activity are required in one tissue versus another at different
times of development. Consistent with this idea, such a cell type speciﬁc
proliferation requirement has been postulated in the pathogenesis of
TCS [51].
While tremendous inroads have been made in understanding the
many levels of regulation controlling gene expression, the regulatory
control of protein production has garnered much less attention. The
historic idea that ribosomes function constitutively to translate the
genetic code has recently been challenged. An emerging idea is that
ribosomes are specialized, built diversely of different rRNAs and combi-
nations of ribosomal proteins and associated factors with variable post-
translational modiﬁcations. This diversity has a considerable impact on
how an mRNA template is translated into functional protein. Even core
ribosome components are now thought to exert selective activity by
virtue of their interactions with speciﬁc cis-acting regulatory elements
that are present within subsets of mRNAs [134]. Thus ribosome activity
appears to be highly regulated and this may provide an important new
mode for governing spatiotemporal gene expression during normal em-
bryonic development and in the pathogenesis of congenital skeletal
anomalies.
A common feature shared by TCS, POADS and DBA, is craniofacial
skeletal malformations caused by perturbations of neural crest cell de-
velopment. This phenotypic overlap likely reﬂects a commonmolecular
function for these proteins in ribosome biogenesis during craniofacial
development. Thus, it will be important to understand how TCOF1,
POLR1C, POLR1D, ribosomal proteins, and DHODH are functionally inte-
grated in neural crest cell-derived bone. However, TCS, POADS and DBA
exhibit distinct abnormalities of the skeleton and this reﬂects the need
to better understand the individual roles of these proteins in skeletal de-
velopment. Understanding how themechanisms of disease overlap and
diverge in ribosomopathies with skeletal defects will be instrumental in
designing realistic avenues for their therapeutic prevention.
Under normal cellular growth conditions, Mdm2 targets p53 for
degradation through polyubiquitination. In contrast, under conditions
of perturbed ribosome biogenesis and nucleolar stress, unincorporated
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capacity. This leads to activation and stabilization of p53 and ultimately
cell death [135,136]. As a case in point, direct inhibition of p53
dependent apoptosis can successfully prevent the manifestation
of ribosomopathy disorders such as TCS (Tcof1) and DBA (Rps19)
[52,65]. However, p53 functions as a tumor suppressor and any inhibi-
tion of p53 would therefore carry a substantial risk of cancer or tumor-
igenesis side effects. This highlights the need to explore other avenues
for ribosomopathy prevention. Interestingly, L-leucine supplementation
has recently been used to successfully treat DBA in humans [68,69] and
animalmodels [66,67]. Embryonic zebraﬁsh andmicewhichmodel DBA
showed considerably improved craniofacial and hematopoietic devel-
opment when their diets were supplemented with L-leucine [66,67].
The mechanistic basis for this is in the craniofacial region, is that
L-leucine stimulates ribosome biogenesis through the mTOR pathway
and thus counters the p53 dependent apoptotic loss of neural crest
cells. Thus L-Leucine supplementation may be a possible treatment
option for other disorders of ribosome biogenesis. Consistent with this
idea, L-leucine was recently shown to ameliorate the development of
Roberts syndrome-like abnormalities in zebraﬁsh and patient speciﬁc
cell based models of the disorder [137].
The disorders described in this review arise due to deﬁcient ribo-
some biogenesis. However, the converse is also likely to be true, that ex-
cessive ribosome biogenesis can also lead to skeletal anomalies. Itmight
be expected that perturbations in signals that lie upstream to regulate
levels of ribosome biogenesis in bone may be able to elicit such effects.
Consistent with this idea, it has long been known that signaling mole-
cules such as FGF, BMP, Wnt, and Hedgehog spatiotemporally regulate
growth, proliferation and differentiation in the craniofacial, limb and
axial skeleton. Yet, how these signals are integrated with ribosome
biogenesis as a means to adapt to changing requirements for protein
synthesis during bone formation and homeostasis is unclear. Resolving
this issue will provide a better understanding of why bone is particular-
ly sensitive to levels of ribosome biogenesis. The convergence of devel-
opmental signaling pathways with ribosome biogenesis can provide
additional levels of translational speciﬁcity to inﬂuence fundamental
aspects of cell growth and proliferation in the context of embryonic
development, evolution and congenital disease.
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